| Cat.No. | Name | Information |
|---|---|---|
| M2331 | PP2 (AGL 1879) | PP2 is a selective inhibitor of Src-family tyrosine kinases with >10,000-fold selectivity over ZAP-70 and JAK2. |
| M1701 | Dasatinib | Dasatinib (BMS-354825) is a small molecule inhibitor of both the SRC and BCR/ABL tyrosine kinases, with IC50's for the isolated kinases of 0.55 and 3.0 nM, respectively. |
| M1648 | AP24534 | Ponatinib (AP24534) is a novel potent, orally available small molecule multitargeted kinase inhibitor of BCR-ABL, PDGFRα, c-Src, c-Kit, FGFR and VEGFR. |
| M1799 | Imatinib Mesylate | Imatinib Mesylate is a Bcr-Abl tyrosine kinase inhibitor, with IC50 values of 2.9 and 3.9 μM for the inhibition of T-cell proliferation stimulated by PHA and DCs respectively. |
| M1685 | Bosutinib | Bosutinib (SKI-606) is a novel Bcr-Abl inhibitor with IC50 values of 0.1 to 0.3 umol/L. |
| M3194 | Nocodazole | Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM, respectively. |
| M8311 | MLR-1023 | MLR-1023 (Tolimidone) is a potent, orally active, allosteric activator of the non-receptor Src-related Lyn kinase that produces lasting glucose lowering, reduces HbA1c levels, and preserves pancreatic β-cells in db/db mice. |
| M8255 | DPH | DPH is a potent cell permeable c-Abl activator, which displays potent enzymatic and cellular activity in stimulating c-Abl activation. |
| M8160 | Src Inhibitor-1 | Src interactivator -1 is a highly selective, ATP-competitive, two-site Src tyrosine kinase Inhibitor with IC50 values of 44 nM and 88 nM against Src and Lck, respectively. It also inhibits Csk and Yes. |
| M7569 | AMG-47a | AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice. |
| M6367 | A 419259 trihydrochloride | A 419259 trihydrochloride is a inhibitor of Src family kinases. |
| M6305 | Olverembatinib | Olverembatinib is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively. |
| M5916 | Radotinib | Radotinib is a selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM, used to treat Chronic Myeloid Leukemia. |
| M5553 | Dasatinib Monohydrate | Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively. |
| M5552 | Dasatinib HCl | Dasatinib(BMS-354825) hydrochloride is a potent and dual Abl/ Src inhibitor IC50 of ＜1 nM/0.8 nM respectively; also inhibit c-Kit (WT)/c-Kit (D816V) with IC50 of 79 nM/37 nM. |
| M5330 | Nilotinib (monohydrochloride monohydrate) | Nilotinib (AMN-107) is a Bcr-Abl inhibitor with IC50 less than 30 nM. |
| M5190 | GNF-7 | GNF-7 is the first type II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design next generation Bcr-Abl kinase inhibitors. |
| M4843 | SU6656 | SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively. |
| M4540 | Scutellarein | Scutellarein is a natural flavonoid with anti-inflammatory effects. |
| M3778 | PF-562771 | PF-562771 is a potent Bcr-Abl inhibitor. In a murine model, AP23848 inhibited activation-loop mutant Kit phosphorylation and tumor growth. |
| M3676 | WH-4-023 | WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM, respectively. |
| M3151 | KX1-004 | Kx1-004 is an effective small molecule inhibitor of SRC-PTK and can be used as a potential protective compound of NIHL. |
| M2953 | PP1 | PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM. |
| M2917 | PD173955 | PD173955 is a potent Bcr-Abl inhibitor with IC50 of 1-2 nM, also inhibiting Src activity with IC50 of 22 nM. |
| M2862 | MNS | MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively. |
| M2749 | GZD824 Dimesylate | GZD824 is a third-generation oral effective BCR-ABL inhibitor, acting on BCR-ABL (WT) and BCR-ABL (T315I) with IC50 of 0.34 nM and 0.68 nM, respectively. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
